BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 4th, before market open. The consensus EPS Estimate is -$1.65 (+50.9% Y/Y) and the consensus Revenue Estimate is ...

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...